- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options | 1 | CNW | ||
| 26.08. | Vector Science and Therapeutics Corp: Vector hires RedChip for investor relations services | 1 | Stockwatch | ||
| 24.08. | Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online | 1 | CNW | ||
| 20.08. | Vector Science and Therapeutics Corp: Vector files patent for peptide orthopedic platform | 2 | Stockwatch | ||
| 20.08. | Vector Sciences & Therapeutics: Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides | 217 | PR Newswire | Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own... ► Artikel lesen | |
| 19.08. | Vector Science and Therapeutics Corp: Vector Science launches quality analytical testing | 1 | Stockwatch | ||
| 17.08. | Vector Science and Therapeutics Corp: Vector, LyoGenesis amend licence, manufacturing deal | 1 | Stockwatch | ||
| VECTOR SCIENCE AND THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.08. | Vector Sciences & Therapeutics: Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings | 189 | PR Newswire | Long-term agreement secures U.S.-based, cGMP manufacturing capacity for Vector's proprietary peptide platform, with quality testing performed by its affiliate Verlytix
... ► Artikel lesen | |
| 29.07. | Vector Science and Therapeutics Corp: Vector Science related company signs MOU with Wynn | 5 | Stockwatch | ||
| 28.07. | Vector Sciences & Therapeutics: Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products | 185 | PR Newswire | MEQUON, Wis. and LENEXA, Kan., July 28, 2026 /PRNewswire/ -- LyoGenesis Plus 1, LLC ("LyoGenesis Plus"), a company related to Vector Science & Therapeutics Corp.... ► Artikel lesen | |
| 25.07. | Vector Science and Therapeutics Corp: Vector files first financials since going public | 1 | Stockwatch | ||
| 25.07. | Vector Sciences & Therapeutics: Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28 | 2.002 | PR Newswire | Peptide manufacturing vertical on track to begin generating revenue in August 2026; VectorMist 510(k) submission advancing toward FDA filing
MEQUON, Wis., July... ► Artikel lesen | |
| 22.07. | Vector Science and Therapeutics Corp: Vector Science to build distributor network | 1 | Stockwatch | ||
| 21.07. | Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels | 1 | CNW | ||
| 17.07. | Vector Science and Therapeutics Corp: Vector partners with Caresyntax on VectorMist data | 1 | Stockwatch | ||
| 17.07. | Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist | 1 | CNW | ||
| 15.07. | Vector Science and Therapeutics Corp: Vector files 15 patent applications over two years | 1 | Stockwatch | ||
| 15.07. | Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies | 2 | CNW | ||
| 09.07. | Vector Science and Therapeutics Corp: Vector Science appoints Drake as Valor president | 1 | Stockwatch | ||
| 08.07. | Valor by Vector Science & Therapeutics: Darryl Drake Jr. Named President of Valor as Vector Science and Therapeutics Targets the Performance Medicine Market | 484 | PR Newswire | SAN BERNARDINO, Calif., July 8, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today announced... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 43,295 | -1,35 % | AKTIEN IM FOKUS: Zinsanstieg birgt Gefahren für sichere Aktienhäfen | FRANKFURT (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten haben zum Wochenbeginn die Aktienkurse von als sichere Anlagen geltenden Unternehmen belastet. Dazu zählen unter anderen die Immobilienwerte... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,280 | +1,61 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,620 | +0,49 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| BILLIONTOONE | 99,50 | 0,00 % | Canaccord initiates BillionToOne stock coverage with buy rating | ||
| HEARTFLOW | 48,880 | 0,00 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 13,530 | 0,00 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,75 | +0,03 % | Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth? | ||
| GERRESHEIMER | 29,840 | +1,51 % | PRESSESPIEGEL/Unternehmen: VOLKSWAGEN, BERTELSMANN, GERRESHEIMER, GLENCORE/RADIANT, AIRBUS | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
VOLKSWAGEN - Im Machtkampf um das nächste Sanierungspaket bei Volkswagen... ► Artikel lesen | |
| SANARA MEDTECH | 34,740 | +0,03 % | Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) | FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 22,790 | +0,13 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BETA BIONICS | 19,410 | -0,05 % | Beta Bionics, Inc.: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,580 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,140 | -1,87 % | EQS-DD: Carl Zeiss Meditec AG: Justus Felix Wehmer, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
04.09.2026 / 17:25... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,730 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PROGYNY | 25,930 | 0,00 % | Progyny stock price target maintained at $31 by Citizens on new offering |
Das Unternehmen VECTOR SCIENCE AND THERAPEUTICS CORP kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VECTOR SCIENCE AND THERAPEUTICS CORP finden Sie auf Wallstreet Online.